Skip to content
School of Pharmacy

team: Center for Pharmacy Practice Transformation

/department-of-pharmacy/research/center_for_pharmacy_practice_transformation/faculty/

Andy Stergachis

Education

  • PhD in Social & Administrative Pharmacy, University of Minnesota
  • MS in Pharmacy Administration, University of Minnesota
  • BPharm Pharmacy, Washington State University

Courses Taught

  • Pharm 581/GH 543: Global Health Pharmacy

Biography

Andy Stergachis is Professor of Pharmacy and Global Health and Adjunct Professor of Health Services and Epidemiology, and Director of the Global Medicines Program, University of Washington. He is an author of 237 peer-reviewed publications in areas such as drug safety, pharmaceutical outcomes, and clinical epidemiology. A licensed pharmacist, he served as Editor-in-Chief of the Journal of the American Pharmacists Association for 6 years until 2019. He is a member of the CEPI Maternal Immunization Working Group; Chair of the Scientific Advisory Board for the Pregnancy Registry to Assess the Safety of Antimalarial use in Pregnancy, and Member, Executive Board, Safety Platform for Emergency Vaccines (SPEAC), Brighton Collaboration, The Task Force for Global Health. He is an elected member of the National Academy of Medicine, and Fellow of the International Society for Pharmacoepidemiology, American Pharmacists Association, American Association for the Advancement of Science, Washington State Pharmacy Association, and the Washington State Academy of Science. Since 2010, He has chaired multiple student doctoral dissertation committees, mentored postdoctoral trainees, served as member of numerous graduate student PhD dissertation and MPH thesis committees, and served as advisor to multiple graduate students.
His research has made major contributions to advancing the safety of medications and vaccines. He has developed and evaluated novel approaches for safety surveillance of vaccines and essential medicines, including medicines for HIV/AIDS, as well as for the evaluating innovative pharmacy-based services in low- and middle-income countries. His recent projects include pharmacovigilance system strengthening; active safety surveillance of TB preventive therapy for PLHIV; sentinel site readiness for maternal immunization active safety surveillance; global burden of antimicrobial resistance; and evaluating and optimizing a virtual care model for PrEP delivery. He is currently PI of the University of Washington component of the Background Incidence Rates in Africa project funded by the Gates Foundation and co-investigator with several other global medicines projects, including with the Institute for Health Metrics and Evaluation on the global burden of antimicrobial resistance. Through his affiliation with the Northwest Center for Public Health Practice, he also works on workforce development and research in emergency preparedness with the public health community.

Selected Publications

  • Wittenauer R, Bacci J, Shah P, Stergachis A. Vaccination payments in states with provider status: a claims analysis. J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102301. doi: 10.1016/j.japh.2024.102301. Epub 2024 Nov 23 1
  • Munoz FM, Kampmann B, Stergachis A, Chaudhary M, Cutland CL, Khalil A, Gentile A, Jones CE, Marshall H, Sevene E, Darko DM, Swamy G, Hyde TB, Voss G, Muelen AS. A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women. Vaccine. 2025 Jul 18;62:127513.
  • Bardach A, Brizuela M, Berrueta M, Ciapponi A, Sambade JM, Ballivian J, Ortega V, Castellana N, Comandé D, Parker EPK, Kampmann B, Stegelmann K, Xiong X, Stergachis A, Munoz FM, Buekens P, Mazzoni A. Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines. Hum Vaccin Immunother. 2025 Dec;21(1):2463191.
  • GBD 2021 Global Stillbirths Collaborators. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021. Lancet. 2024 Nov 16;404(10466):1955-1988. (co-author).
  • GBD 2023 Vaccine Coverage Collaborators. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037-2 (co-author)
  • Chaudhary M, Cutland CL, Bonet M, Gentile A, Jones CE, Marshall HS, Stergachis A, Voss G, Darko DM, Sevene E, Hyde T, Fairlie L, Kampmann B, Everett D, Munoz FM. Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine. 2024 Nov 1;43:126479.
  • Ciapponi A, Berrueta M, Argento FJ, Ballivian J, Bardach A, Brizuela ME, Castellana N, Comandé D, Gottlieb S, Kampmann B, Mazzoni A, Parker EPK, Sambade JM, Stegelmann K, Xiong X, Stergachis A, Buekens P. Safety and Effectiveness of COVID-19 Vaccines during Pregnancy: A Living Systematic Review and Meta-Analysis. Drug Safety. Drug Saf. 2024 Jul 15.
  • Montaño MA, Chen Y, Saldarriaga EM, Thuo N, Kiptinness C, Stergachis A, Mugambi ML, Ngure K, Ortblad KF, Sharma M. Willingness to pay for HIV pre- and post-exposure prophylaxis services delivered via an online pharmacy in Kenya. BMC Health Serv Res. 2025 Apr 22;25(1):576. doi: 10.1186/s12913-025-12766-x. PMID: 40264148.
  • Chen Y, Montaño MA, Naik P, Thuo N, Kiptinness C, Rafferty M, Stergachis A, Mugambi ML, Ngure K, Ortblad KF, Sharma M. Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya. J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003680. Epub ahead of print. PMID: 40198924.
  • Sahu M, Wagner TD, Thomson A, Beauchamp M, Campbell JD, Crosby S, DeJarnatt D, Lescinsky H, Salih RK, Taylor K, Weil M, Dwyer-Lindgren L, Haakenstad A, Scott JW, Stergachis A, Essien UR, Dieleman JL. Variation in Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State. JAMA Health Forum. 2025 Aug 1;6(8):e252329.

Peggy Soule Odegard

Education

  • PharmD, University of Washington
  • Bachelor of Science in Pharmacy, UW

Research Interests

  • Practice advancement and diabetes

Courses Taught

  • Phrmcy 501: Foundations of Being a Pharmacist I
  • Phrmcy 502: Foundations of Being a Pharmacy II
  • Phrmcy 503: Advanced Pharmacy Leadership
  • Pharmacy 588: Diabetes Care
  • Pharmacy 557: Introduction to Therapeutics

Biography

Peggy Odegard, BS Pharm, PharmD, CDES, having served as the Interim Dean for the School of Pharmacy in 2022-2023, and an active pharmacist practitioner. She earned her Doctor of Pharmacy and Bachelor of Science in Pharmacy degrees from the University of Washington.

Dr. Odegard oversees the UW School of Pharmacy Doctor of Pharmacy program and is advanced diabetes care pharmacist clinician. She provides regular outreach and community-based education to older adults and to those affected by diabetes, mentoring students alongside her in this role. Her research and teaching are focused on diabetes care, pharmacy practice advancement, interprofessional education, and leadership. Dr. Odegard has published more than 60 refereed manuscripts and book chapters, and regularly presents her work nationally.

Dr. Odegard is past Chair of the UW School of Pharmacy, Department of Pharmacy and prior to her work at the UW, served as the Clinical Pharmacy Manager for a regional health system, where she gained substantial experience and training in organizational leadership, change management, and with quality improvement and implementation of pharmacy practice services.

Selected Publications

https://www.ncbi.nlm.nih.gov/pubmed/?term=odegard+ps

Ryan Hansen

Education

  • PhD in Pharmaceutical Outcomes Research and Policy, UW
  • PharmD, UW
  • Bachelor of Arts in Chemistry and Philosophy, Carroll College

Research Interests

  • Cost-effectiveness modeling
  • Comparative effectiveness research
  • Medication safety

Courses Taught

  • PHRMCY 512: Fundamentals of US Health Care, Pharmacy Safety and Law
  • HEOR 505: Managed Care Pharmacy
  • HEOR 530: Economic Evaluation in Health and Medicine
  • HEOR 532: Advanced Methods in Economic Evaluation
  • HEOR 545: Pharmaceutical and Medical Policy Evaluation
  • HEOR 597: Graduate Seminar

Biography
Dr. Hansen is Professor of Pharmacy and Chair of the Department of Pharmacy. His primary research interests focus on the comparative safety of prescription medications, health technology assessment, and health care system efficiency. He received his Bachelor of Arts from Carroll College, and his Doctor of Pharmacy and Doctor of Philosophy from the University of Washington.

Selected Recent Publications

Elsisi, Z, Canestaro WJ, Steuten L, Hansen RN. Applying Early Health Technology Assessment (e-HTA) to Inform Investment in Novel Health Technologies in the US. International Journal of Technology Assessment in Health Care 2025. In Press.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Adverse respiratory events during treatment with gabapentin and opioids among older adults with spine-related conditions: a propensity-matched cohort study in the US Medicare population. Spine 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD, Fendrick AM. Projected Out of Pocket Savings of the Medicare Part D Two Dollar Drug List Model. JAMA 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD. Overpayment for Generic Drugs under Medicare Part D: Consequences on Patient Out-of-Pocket Costs. JAMA Health Forum 2025;6(2):e250012.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Mortality after concurrent treatment with gabapentin and opioids in older adults with spine diagnoses. PAIN 2024. In Press.

Cousin EM, Sullivan SD, Hansen RN, Gabriel N, Kirihennedige AS, Hernandez I. Drugs Anticipated to Be Selected for Medicare Price Negotiation in 2025 for Implementation in 2027. Journal of Managed Care & Specialty Pharmacy 2024;30(11): 1203-1210.

Tran J, Mishra A, Zimmerman M, Hansen RN. Bridging PrEP Access Gaps: Mapping Geospatial Accessibility Across the US and Leveraging Community Pharmacies for Expansion. Journal of the American Pharmacists Association 2024. In Press.

Hernandez I, Sullivan SD, Hansen RN, Fendrick AM. Cheaper Isn’t Always Better: Drug Shortages in the U.S. and A Value-Based Solution to Alleviate Them. Journal of Managed Care & Specialty Pharmacy 2024;30(7):719-26.

Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Kubiniec RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug and Alcohol Dependence Reports 2024. In Press.

Green TC, Silcox J, Bolivar D, Gray M, Floyd AS, Irwin AN, Hansen RN, Hartung D, Bratberg J. Pharmacy staff-reported adaptations to naloxone provision and over the counter (OTC) syringe sales during the COVID-19 pandemic: experiences across multiple states and two pharmacy chains. Journal of the American Pharmacists Association 2024;64(1):71-78.

Hernandez I, Gabriel N, Kaltenboeck A, Boccuti C, Hansen RN, Sullivan SD. Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors. JAMA 2023;330(24):2390-92.

Tabah A, Gold LS, Marcum ZA, Hansen RN. Antidepressants and the Risk of Fall-related Injury in Older Adults with Incident Depression in the United States: A Comparative Safety Analysis. Pharmacoepidemiology 2023. In Press.

Bacci, JL, Marcum ZA, Rodriguez P, Hansen RN, Bansal A, Pfund T, Kim JJ, Odegard P. Community pharmacist intervention to optimize statin adherence in diabetes care: The GuIDE-S study. Journal of the American Pharmacists Association 2023;63(3):946-51.

Jiao B, Fredricks DN, Srinivasan S, Hansen RN. Economic Evaluation of a Point-of-Care Test for Bacterial Vaginosis among Women with Vaginal Symptoms. Sexually Transmitted Diseases 2023;50(5):310-6.

Jiang S, Seslar SP, Sloan LA, Hansen RN. Healthcare Resource Utilization and Costs Associated with Atrial Fibrillation and Rural-urban Disparities. Journal of Managed Care and Specialty Pharmacy 2022;28(11):1321-30.

Nitkin D, Lin GA, Campbell JC, Hansen RN, Brouwer E, Chen Y, Herron-Smith S, Agboola F, Pearson SD. The Effectiveness and Value of Tirzepatide for Type 2 Diabetes Mellitus. Journal of Managed Care and Specialty Pharmacy 2022;28(6):680-4.

Ko GC, Hansen RN, Carlson JJ. Comparing Costs and Healthcare Resource Utilization Between nmHSPC and mHSPC Patients: A Retrospective Claims Analysis. Journal of Managed Care and Specialty Pharmacy 2022;28(3):287-95.

Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD. JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value. Journal of Managed Care and Specialty Pharmacy 2022;28(1):108-14.

Bratburg J, Irwin A, Hartung D, Floyd A, Bogis J, Hansen RN, Green T. Study Protocol for the Respond to Prevent Study: A multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Substance Abuse 2022;41(3):901-5.

Hansen RN, Saour B, Serafini B, Hannaford B, Kim L, Kohno T, James R, Monsky W, Seslar S. Opportunities and Barriers to Rural Telerobotic Surgical Healthcare in 2021: Report and Research Agenda from a Stakeholder Workshop. Telemedicine and e-Health 2022;28(7):1050-7.

Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. ‘Treat my whole person, not just my condition’: Qualitative explorations of Hepatitis C care delivery preferences among people who inject drugs. Addiction Science and Clinical Practice 2021;16 (1):52.

Pocobelli G, Akosile MA, Hansen RN, Eavey J, Wellman RD, Johnson RL, Carls G, Bron M, Dublin S. Obstructive Sleep Apnea and Risk of Motor Vehicle Accident. Sleep Medicine 2021;85:196-203.

Banta-Green CJ, Hansen RN, Ossiander EM, Wasserman CR, Merrill JO. Buprenorphine utilization among all Washington State residents based upon prescription monitoring program data- Characteristics associated with two measures of retention and patterns of care over time. Journal of Substance Abuse Treatment 2021;127:108446 epub.

Brouwer E, Yeung K, Barthold D, Hansen RN. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in one mid-size integrated health system. Journal of Managed Care and Specialty Pharmacy 2021;27(6):732-42.

Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Cost-Effectiveness of Oral Semaglutide Added to Current Antihyperglycemic Treatment for Type 2 Diabetes. Journal of Managed Care and Specialty Pharmacy 2021;27(4):455-68.

Landaas EJ, Baird GS, Hansen RN, Flum DR, Sullivan SD. Integrating Formal Technology Assessment into an Integrated Healthcare Delivery System: Smart Innovation. International Journal of Health Technology Assessment in Health Care 2020;36(1):58-63.

Tice JA, Guzauskas GF, Hansen RN, Herron-Smith S, Segel C, Walsh JME, Pearson SD. The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. Journal of Managed Care and Specialty Pharmacy 2020;26(5):620-3.

Gold LS, Nazareth TA, Yu T, Fry KR, Mahler N, Rava A, Waltrip RW, Hansen RN. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms. Pediatric Health, Medicine and Therapeutics 2019;10:195-207.

Gold LS, Patrick DL, Hansen RN, Goss CH, Kessler L. Correspondence between Lung Function and Symptom Measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Journal of Cystic Fibrosis 2019;18(6):886-93.

Bacci JL, Hansen RN, Ree C, Reynolds MJ, Stergachis A, Odegard PS. The effects of vaccination forecasts and value-based payment on adult immunizations by community pharmacists. Vaccine 2019;37(1):152-9.

Shelly Gray

Education

  • PharmD, University of Michigan
  • MS in Epidemiology, University of Washington

Courses Taught

  • PHARM 562: Pharmacotherapeutics V
  • PHARM 550: Seminar in Geriatrics

Research Interests

  • Medication safety in older adults
  • Deprescribing
  • Medication use and risk for falls, fractures, dementia

Biography

Dr. Gray has been a faculty member in the UW Department of Pharmacy since 1992. She is an investigator on numerous federally funded research grants and is author of more than sixty peer-reviewed publications. Earlier in her career, she received an American Association of Colleges of Pharmacy New Investigator Award and a Career Development Award from the National Institute on Aging. She serves on the editorial board for the “Annals of Pharmacotherapy”, “Journal of the American Geriatrics Society” and “Research in Gerontological Nursing”.

Gray has served as a consultant pharmacist for Providence Elderplace. Previously, she completed a two-year fellowship in geriatrics at the University of North Carolina at Chapel Hill and a clinical pharmacy residency at Thomas Jefferson University Hospital in Philadelphia. She has served on various committees of pharmacy and geriatric professional organizations.

Selected Publications

  • Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015:2175(3):401-7.
  • Gray SL, Dublin S, Yu O, Walker R, Anderson M, Crane P, Larson E. Benzodiazepine use and risk of incident dementia or cognitive decline. BMJ. 2016;352:i90.
  • Gray SL, Walker RL, Dublin S, Yu O, Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk. J Am Geriatr Soc. 2018;66(2):247-253.
  • Gray SL, Anderson ML, Hanlon JT, Dublin S, Walker R, Hubbard, RA, Yu O, Montine T, Sonnen J, Keene CD, Crane PK, Larson EB. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. J Alzheimers Dis 2018;65(2):607-616.

Beth Devine

Education

  • MSc, Medical Statistics and Health Data Science, University of Bristol
  • Post-doctoral Fellowship, The CHOICE Institute, UW and Roche Global Pharma Business
  • PhD, Health Services Research, UW
  • MBA, University of San Francisco
  • PharmD, University of the Pacific
  • Clinical Pharmacy Residency, Palo Alto VA Medical Center

Research Interests

  • Evidence synthesis; systematic reviews, meta-analysis, network meta-analysis using Bayesian and frequentist methods.
  • Precision medicine: pharmacogenomics; genomic risk for hereditary cancers.
  • Health technology assessment and outcomes research including preference-based methods, discrete choice experiments and multi-criteria decision analysis.
  • Comparative effectiveness research in the context of clinical informatics.
  • Real world evidence of costs and outcomes.
  • Medication safety.

Biography

Beth Devine is Professor Emerita at The CHOICE Institute, School of Pharmacy Prior to becoming emerita, she held adjunct professorships in the Department of Health-Systems and Population Health, School of Public Health and the Department of Biomedical Informatics, School of Medicine.

She also held the Shirley and Herb Bridge Endowed Professor for Women in Pharmacy (2021-2023). She is currently a Visiting Professor at the University of Bristol, UK (2024-2026). She was a Fulbright US Scholar to the University of Murcia, Spain (2021-2022) and an Honorary Professor there (2022-2023).

She is currently president-elect of ISPOR – The Professional Society for Health Economics and Outcomes Research (2025-2026), was a member of the Board of Directors of ISPOR (2021-2024) and is an Associate Editor for the ISPOR journal Value in Health (2021-2029). She served on the ISPOR Task Force that developed guidelines to conduct network meta-analyses (2009-2011) and is currently co-chairing the ISPOR Task Force to update to these guidelines (2026). From 2014-2025 she served as an Assistant Director of the AHRQ-funded Pacific Northwest Evidence-based Practice Center. In 2013, she was elected as a member of the Society for Research Synthesis Methodology.

Prior to joining the faculty at the UW, Dr. Devine was an advanced practice (prescribing) clinical pharmacist and led the Pharmacy & Therapeutics Committee at the University of California San Francisco. where she served a term as president of the California Society of Health-System Pharmacists, earning their Lifetime Achievement Award for her leadership role in advancing the scope of practice for California pharmacists through legislation (1994).

Courses Taught

  • HEOR DS 510: Data Science in Health Economics and Outcomes Research
  • HECON 530 – Health Technology Assessment in a Global Environment
  • HEOR 531/HSERV 584 – Assessing Outcomes in Health & Medicine
  • PHRMCY 514 – Design and Analysis of Medical Studies

Selected Peer-Reviewed Publications

MyNCBI Bibliography
https://www.ncbi.nlm.nih.gov/myncbi/emily.devine.1/bibliography/public/

Google Scholar Profile: (n = 336; citations: 11294; h-index = 43, i10-index = 128)
https://scholar.google.com/citations?user=Wor4Qv0AAAAJ&hl=en

Jennifer Bacci

Education:

  • PharmD, University of Pittsburgh School of Pharmacy
  • MPH, University of Pittsburgh School of Public Health

Research Interests:

  • Community-based pharmacy practice
  • Implementation science
  • Prevention and public health

Courses Taught: 

  • PHRMCY 501: Foundations of Being a Pharmacist I
  • PHRMCY 502: Foundations of Being a Pharmacist II
  • PHARM 523: Insights into Community Pharmacy Practice Transformation

Biography: 

Dr. Bacci is the Endowed Associate Professor of Innovative Pharmacy Practice at the University of Washington School of Pharmacy. Her research focuses on the application of implementation science to evaluate and advance the adoption of innovative patient care models in community pharmacy practice, including childhood and adult vaccinations, point-of-care testing, chronic disease management, pharmacist prescribing, and medical billing. Dr. Bacci collaborates closely with community partners to address needs and challenges faced by practitioners and patients and amplify the positive impact of community-based pharmacy teams.

Dr. Bacci practiced in community pharmacy for 10 years in chain and independent settings and is a Board Certified Ambulatory Care Pharmacist (BCACP). She remains highly engaged in practice as a member of the Washington State Pharmacy Association (WSPA) Board of Directors, a Network Facilitator for CPESN WA, a clinically integrated network of independent pharmacies in Washington State, and as a leader in the Academia-Community Transformation (ACT) Pharmacy Collaborative, a nationwide collaboration to support and facilitate community pharmacy practice transformation efforts.

Dr. Bacci has been honored with the 2021 Albert B. Prescott Pharmacy Leadership Award and 2019 Washington State Distinguished Young Pharmacist of the Year Award. Dr. Bacci and her research collaborators have been recognized with the 2018 NAIIS “Immunization Neighborhood” Adult Immunization Champion Award and 2018 American Pharmacist Association Immunization Champion Award.

Dr. Bacci completed her PharmD at PittPharmacy in 2011 followed by followed by a PGY-1 Community-based Pharmacy Residency with PittPharmacy and Rite Aid. After working full-time in community practice, she returned to PittPharmacy to complete a two-year Community Pharmacy Research Fellowship.

Selected Publications:

Wittenauer R, Shah PD, Bacci JL, Stergachis A. Locations and characteristics of pharmacy deserts in the United States: a geospatial study. Health Aff Sch. 2024;2(4):qxae035. Published 2024 Mar 16. doi:10.1093/haschl/qxae035

Bacci JL, English C, Odegard PS, Stergachis A, Snyder CR, Danielson JH. A 2023 Washington State pharmacist workforce survey: Employment and patient care roles. J Am Pharm Assoc (2003). 2025;65(1):102314. doi:10.1016/j.japh.2024.102314

Bacci JL, Nwogu IB, Zaraa S, et al. A community pharmacist intervention for people living with epilepsy. J Am Pharm Assoc (2003). 2025;65(1):102275. doi:10.1016/j.japh.2024.102275

Bhardwaj S, Galanter N, Berenbrok LA, Shah PD, Bacci JL. Pediatric vaccination in pharmacies is not associated with delayed well-child visits among commercially insured children. Health Aff Sch. 2025;3(2):qxaf028. Published 2025 Feb 10. doi:10.1093/haschl/qxaf028

Bacci JL, Marcum ZA, Rodriguez P, et al. Community pharmacist intervention to optimize statin adherence in diabetes care: The GuIDE-S study. J Am Pharm Assoc. 2023;63(3):946-951. doi:10.1016/j.japh.2023.03.002

Bacci JL, Rodriguez T, Hansen R, et al. Community pharmacist intervention to close statin gaps in diabetes care: The GuIDE-S study. J Am Pharm Assoc. 2023;63(1):108-117. doi:10.1016/j.japh.2022.08.025

Bacci JL, Coley K, Daly C, et al. Qualitative analysis of community pharmacy practice transformation. J Am Coll Clin Pharm. 2022; 5(12):1236-1252. doi:10.1002/jac5.1728

Bacci JL, Odegard P, Arnold J, Stergachis A. Strengthening pandemic preparedness through pharmacy and public health collaborations: Findings from a facilitated discussion exercise. J Am Pharm Assoc. 2021;61(3):e99-e106. doi:10.1016/j.japh.2020.12.024

Bacci JL, Zaraa S, Stergachis A, Simic G, White HS. Community pharmacists’ role in caring for people living with epilepsy: A scoping review. Epilepsy Behav. 2021;117:107850. doi:10.1016/j.yebeh.2021.107850

Bacci JL, Hansen R, Ree C, Reynolds MJ, Stergachis A, Odegard PS. The effects of vaccination forecasts and value-based payment on adult immunizations by community pharmacists. Vaccine. 2019;37(1):152-159. doi:10.1016/j.vaccine.2018.11.018

Wang AB, Bacci JL, Amoo M, Ree C, Firebaugh R, Odegard P. Impact of an immunization platform in community pharmacies. J Am Pharm Assoc. 2019;59(4S):S151-S155. doi:10.1016/j.japh.2019.05.007

Akers JL, Meer G, Kintner J, Shields A, Dillon-Sumner L, Bacci JL. Implementing a pharmacist-led in-home medication coaching service via community-based partnerships. J Am Pharm Assoc. 2019;59(2):243-251. doi:10.1016/j.japh.2018.11.008